Intensity gets FDA Fast Track for breast cancer drug
Intensity Therapeutics has received an FDA Fast Track designation for its INT230-6 for the treatment of patients with relapsed or metastatic triple negative breast cancer (TNBC)...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
Intensity Therapeutics has received an FDA Fast Track designation for its INT230-6 for the treatment of patients with relapsed or metastatic triple negative breast cancer (TNBC)...
Connecticut is in the top 5 states leading the nation in innovative economies, according to a Bloomberg report. “The state’s defense, aerospace, and biotechnology sectors are...
New therapeutics that harness cellular machinery to degrade targets are entering clinical trials, led by a PROTAC anticancer candidate developed by Arvinas. Whereas most small...
Achillion reports that it achieved threshold enrollment in the Phase 2 trials of ACH-4471 for patients with C3 glomerulopathy (C3G), a devastating disease affecting the...
GSK’s ViiV secured FDA approval for Dovato after submitting a marketing application with a priority review voucher (PRV) last October. The drug is used to treat...
A new collaboration between UConn Health and the Foundation for Prader-Willi Research will create a centralized, high quality biobank of stem cells to help researchers...
Azitra has been awarded a Phase II Small Business Innovation Research (SBIR) grant (#1853071) of $719,700 from the National Science Foundation (NSF). This grant will support...
Tangen Biosciences was founded in 2013 and is located in Branford, Connecticut. The Company has developed an innovative platform that enables molecular diagnostic technology to...
The Jackson Laboratory (JAX) reports that it has signed a research agreement for up to $4.2 million with Sanofi to identify new targets to treat...
New Haven biopharma Trevi Therapeutics is planning to go public in hopes of raising $86 million to pay for late-stage clinical trials of its drug...